Literature DB >> 12842334

The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles.

Sung Hak Lee, Jaekyu Shin, Jae Mook Choi, Eun Young Lee, Dal Hyun Kim, Jung-Woo Suh, Jun Hwan Chang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12842334     DOI： 10.1016/s0924-8579(03)00124-9

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  3 in total

1.  A physiologically based pharmacokinetic model for capreomycin.

Authors:  B Reisfeld; C P Metzler; M A Lyons; A N Mayeno; E J Brooks; M A Degroote
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.

Authors:  L Garcia-Contreras; Pavan Muttil; John K Fallon; Mohan Kabadi; Robert Gerety; Anthony J Hickey
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

3.  Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Authors:  L Garcia-Contreras; J Fiegel; M J Telko; K Elbert; A Hawi; M Thomas; J VerBerkmoes; W A Germishuizen; P B Fourie; A J Hickey; D Edwards
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.